Symbicort

AZ's Symbicort suffers setback

AstraZeneca has been denied approval by the FDA for the use of its asthma drug Symbicort in children aged 6-11 years old. ... Symbicort was approved in the US for use in children over 12 years old for long-term maintenance of asthma in July 2009.

The PM Society Advertising Awards 2008

Highly commended: Zonegran by Big Pink for Eisai Ltd. Winner: Symbicort Smart.

PMEA 2008: Results and winners and pictures

by Pfizer.                                                                                  . Highly Commended. Symbicort SMART Launch. by AstraZeneca in association

Symbicort patent loss drags down AZ's share value

Symbicort racked up FY06 global sales of USD 1.2bn. The EU region accounted for USD 1bn of total sales. ... They also reduced estimates of Symbicort's 2012 sales in the EU region from USD 1.7bn to USD 599m.

Pharma news in brief

The US Food and Drug Administration (FDA) has approved AstraZeneca's (AZ) inhaled asthma drug, Symbicort, for the long-term treatment of patients aged 12 or over - a year earlier than ... AZ plans to market Symbicort in the US in mid-2007. Shares in AZ

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]